Ischemic complications after percutaneous transluminal coronary angioplasty
The ischemic complications of percutaneous transluminal coronary angioplasty (PTCA) include abrupt closure, which occurs in 2% to 10% of patients and is associated with increased morbidity and mortality. Periprocedural myocardial infarction due to side branch occlusion or embolization of platelet ag...
Gespeichert in:
| Veröffentlicht in: | The American Journal of Medicine 2000-03, Vol.108 (4), p.309-316 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 316 |
|---|---|
| container_issue | 4 |
| container_start_page | 309 |
| container_title | The American Journal of Medicine |
| container_volume | 108 |
| creator | Bates, Eric R |
| description | The ischemic complications of percutaneous transluminal coronary angioplasty (PTCA) include abrupt closure, which occurs in 2% to 10% of patients and is associated with increased morbidity and mortality. Periprocedural myocardial infarction due to side branch occlusion or embolization of platelet aggregates or thrombus occurs in 5% to 20% of patients. Patients with acute coronary syndromes, older age, and complex lesions are at greater risk of periprocedural complications. Technical advances, primarily stenting, are useful in the prevention and management of acute closure, but are also accompanied by thrombotic complications. It remains to be seen whether the new antithrombin agents reduce the rate of periprocedural complications if used in combination with aspirin and new antiplatelet therapies. These new antiplatelet agents (ticlopidine, clopidogrel, abciximab, eptifibatide, and tirofiban) reduce the rate of ischemic complications and have become standard adjunctive therapy for patients who undergo PTCA. |
| doi_str_mv | 10.1016/S0002-9343(99)00464-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72299323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002934399004647</els_id><sourcerecordid>72299323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-e279f47bab1252541be3952c5c4f397fd2009df3b542f4408bea86fdcd0d0fed3</originalsourceid><addsrcrecordid>eNqFkF1L5DAUhoO46PjxE5Qii7gX1SRNmsmVLKLu4IAXu16HNDnRSNvUpF3w35txBgVvvAohz3nzngehI4LPCSb1xV-MMS1lxaozKX9hzGpWii00I5zzUpCabqPZB7KL9lJ6zlcseb2DdkmOYIKyGbpbJPMEnTeFCd3QeqNHH_pUaDdCLAaIZhp1D2FKxRh1n9qp871uMx1Dr-NroftHH4ZWp_H1AP1wuk1wuDn30cPN9b-rP-Xy_nZx9XtZGkbEWAIV0jHR6IZQTjkjDVSSU8MNc5UUztJc07qq4Yw6xvC8AT2vnTUWW-zAVvvodJ07xPAyQRpV55OBtl0XVYJSKStaZfDkC_gcppjrJ0XzO6uxqDPE15CJIaUITg3Rd3k1RbBaqVbvqtXKo5JSvatWIs8db8KnpgP7ObVxm4GfG0Ano1uX9RmfPjkq5xKv_r9cY5CV_fcQVTIeegPWRzCjssF_0-QN9DGbjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232346076</pqid></control><display><type>article</type><title>Ischemic complications after percutaneous transluminal coronary angioplasty</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bates, Eric R</creator><creatorcontrib>Bates, Eric R</creatorcontrib><description>The ischemic complications of percutaneous transluminal coronary angioplasty (PTCA) include abrupt closure, which occurs in 2% to 10% of patients and is associated with increased morbidity and mortality. Periprocedural myocardial infarction due to side branch occlusion or embolization of platelet aggregates or thrombus occurs in 5% to 20% of patients. Patients with acute coronary syndromes, older age, and complex lesions are at greater risk of periprocedural complications. Technical advances, primarily stenting, are useful in the prevention and management of acute closure, but are also accompanied by thrombotic complications. It remains to be seen whether the new antithrombin agents reduce the rate of periprocedural complications if used in combination with aspirin and new antiplatelet therapies. These new antiplatelet agents (ticlopidine, clopidogrel, abciximab, eptifibatide, and tirofiban) reduce the rate of ischemic complications and have become standard adjunctive therapy for patients who undergo PTCA.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/S0002-9343(99)00464-7</identifier><identifier>PMID: 11014724</identifier><identifier>CODEN: AJMEAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Angioplasty ; Angioplasty, Balloon, Coronary - adverse effects ; Biological and medical sciences ; Drug therapy ; Fibrinolytic Agents - therapeutic use ; Humans ; Medical sciences ; Myocardial Infarction - etiology ; Myocardial Ischemia - etiology ; Myocardial Ischemia - prevention & control ; Platelet Aggregation Inhibitors - therapeutic use ; Randomized Controlled Trials as Topic ; Risk Factors ; Stents ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the heart</subject><ispartof>The American Journal of Medicine, 2000-03, Vol.108 (4), p.309-316</ispartof><rights>2000 Excerpta Medica Inc.</rights><rights>2000 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Mar 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-e279f47bab1252541be3952c5c4f397fd2009df3b542f4408bea86fdcd0d0fed3</citedby><cites>FETCH-LOGICAL-c417t-e279f47bab1252541be3952c5c4f397fd2009df3b542f4408bea86fdcd0d0fed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002934399004647$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>313,314,776,780,788,3537,27899,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1298906$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11014724$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bates, Eric R</creatorcontrib><title>Ischemic complications after percutaneous transluminal coronary angioplasty</title><title>The American Journal of Medicine</title><addtitle>Am J Med</addtitle><description>The ischemic complications of percutaneous transluminal coronary angioplasty (PTCA) include abrupt closure, which occurs in 2% to 10% of patients and is associated with increased morbidity and mortality. Periprocedural myocardial infarction due to side branch occlusion or embolization of platelet aggregates or thrombus occurs in 5% to 20% of patients. Patients with acute coronary syndromes, older age, and complex lesions are at greater risk of periprocedural complications. Technical advances, primarily stenting, are useful in the prevention and management of acute closure, but are also accompanied by thrombotic complications. It remains to be seen whether the new antithrombin agents reduce the rate of periprocedural complications if used in combination with aspirin and new antiplatelet therapies. These new antiplatelet agents (ticlopidine, clopidogrel, abciximab, eptifibatide, and tirofiban) reduce the rate of ischemic complications and have become standard adjunctive therapy for patients who undergo PTCA.</description><subject>Aged</subject><subject>Angioplasty</subject><subject>Angioplasty, Balloon, Coronary - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Drug therapy</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Ischemia - etiology</subject><subject>Myocardial Ischemia - prevention & control</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Factors</subject><subject>Stents</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the heart</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1L5DAUhoO46PjxE5Qii7gX1SRNmsmVLKLu4IAXu16HNDnRSNvUpF3w35txBgVvvAohz3nzngehI4LPCSb1xV-MMS1lxaozKX9hzGpWii00I5zzUpCabqPZB7KL9lJ6zlcseb2DdkmOYIKyGbpbJPMEnTeFCd3QeqNHH_pUaDdCLAaIZhp1D2FKxRh1n9qp871uMx1Dr-NroftHH4ZWp_H1AP1wuk1wuDn30cPN9b-rP-Xy_nZx9XtZGkbEWAIV0jHR6IZQTjkjDVSSU8MNc5UUztJc07qq4Yw6xvC8AT2vnTUWW-zAVvvodJ07xPAyQRpV55OBtl0XVYJSKStaZfDkC_gcppjrJ0XzO6uxqDPE15CJIaUITg3Rd3k1RbBaqVbvqtXKo5JSvatWIs8db8KnpgP7ObVxm4GfG0Ano1uX9RmfPjkq5xKv_r9cY5CV_fcQVTIeegPWRzCjssF_0-QN9DGbjQ</recordid><startdate>20000301</startdate><enddate>20000301</enddate><creator>Bates, Eric R</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Sequoia S.A</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20000301</creationdate><title>Ischemic complications after percutaneous transluminal coronary angioplasty</title><author>Bates, Eric R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-e279f47bab1252541be3952c5c4f397fd2009df3b542f4408bea86fdcd0d0fed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Angioplasty</topic><topic>Angioplasty, Balloon, Coronary - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Drug therapy</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Ischemia - etiology</topic><topic>Myocardial Ischemia - prevention & control</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Factors</topic><topic>Stents</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the heart</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bates, Eric R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The American Journal of Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bates, Eric R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ischemic complications after percutaneous transluminal coronary angioplasty</atitle><jtitle>The American Journal of Medicine</jtitle><addtitle>Am J Med</addtitle><date>2000-03-01</date><risdate>2000</risdate><volume>108</volume><issue>4</issue><spage>309</spage><epage>316</epage><pages>309-316</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><coden>AJMEAZ</coden><abstract>The ischemic complications of percutaneous transluminal coronary angioplasty (PTCA) include abrupt closure, which occurs in 2% to 10% of patients and is associated with increased morbidity and mortality. Periprocedural myocardial infarction due to side branch occlusion or embolization of platelet aggregates or thrombus occurs in 5% to 20% of patients. Patients with acute coronary syndromes, older age, and complex lesions are at greater risk of periprocedural complications. Technical advances, primarily stenting, are useful in the prevention and management of acute closure, but are also accompanied by thrombotic complications. It remains to be seen whether the new antithrombin agents reduce the rate of periprocedural complications if used in combination with aspirin and new antiplatelet therapies. These new antiplatelet agents (ticlopidine, clopidogrel, abciximab, eptifibatide, and tirofiban) reduce the rate of ischemic complications and have become standard adjunctive therapy for patients who undergo PTCA.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11014724</pmid><doi>10.1016/S0002-9343(99)00464-7</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9343 |
| ispartof | The American Journal of Medicine, 2000-03, Vol.108 (4), p.309-316 |
| issn | 0002-9343 1555-7162 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72299323 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Angioplasty Angioplasty, Balloon, Coronary - adverse effects Biological and medical sciences Drug therapy Fibrinolytic Agents - therapeutic use Humans Medical sciences Myocardial Infarction - etiology Myocardial Ischemia - etiology Myocardial Ischemia - prevention & control Platelet Aggregation Inhibitors - therapeutic use Randomized Controlled Trials as Topic Risk Factors Stents Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the heart |
| title | Ischemic complications after percutaneous transluminal coronary angioplasty |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T01%3A13%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ischemic%20complications%20after%20percutaneous%20transluminal%20coronary%20angioplasty&rft.jtitle=The%20American%20Journal%20of%20Medicine&rft.au=Bates,%20Eric%20R&rft.date=2000-03-01&rft.volume=108&rft.issue=4&rft.spage=309&rft.epage=316&rft.pages=309-316&rft.issn=0002-9343&rft.eissn=1555-7162&rft.coden=AJMEAZ&rft_id=info:doi/10.1016/S0002-9343(99)00464-7&rft_dat=%3Cproquest_cross%3E72299323%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232346076&rft_id=info:pmid/11014724&rft_els_id=S0002934399004647&rfr_iscdi=true |